Spatiotemporal identification of therapeutic markers via dual-targeted SERS bioprobes for assessing breast cancer progression

A dual-targeted SERS strategy enables ultrasensitive detection of PD-L1 and HER2 in breast cancer. With machine learning-assisted SERS, it achieves a spatiotemporal heterogeneity accuracy of >94%.